Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...
Takeaways: Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory...
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Jamieson Wellness to be acquired by Kirin in C$2.5 billion transaction Jamieson Wellness announced that it has entered into a definitive agreement to be acquired by Kirin Holdings Company for C$45.75 ...
Takeaways: Itovebi’s addition to Québec’s RAMQ list means eligible patients with advanced HR‑positive, HER2‑negative, PIK3CA‑mutated breast cancer can now access a targeted pill that, in the INAVO120 ...
Health Canada authorizes P-I clinical trial of Moderna’s mRNA vaccine for Bundibugyo Ebola Health Canada has authorized Moderna to initiate a P-I clinical trial of its candidate mRNA vaccine for Ebola...
Takeaways: The C-POST data – 68% reduction in recurrence or death versus placebo – gives Regeneron a strong clinical story to push Libtayo earlier in the treatment pathway,...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Clinuvel’s Scenesse (afamelanotide) approved in Canada for erythropoietic protoporphyria Health Canada has approved Clinuvel’s Scenesse (afamelanotide) for the prevention of phototoxicity ...
